Infection, Lung ParenchymaPPACNCT05661513
Inventory of the Management of Acute Community-acquired Pneumonia in Strasbourg University Hospitals
An observational study of Infection, Lung Parenchyma, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Infection, Lung Parenchyma
- How many people
- 1,000 participants
- Where
- 1 siteFrance
- Study dates
- 9 Sep 2022to 9 Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adult patients with acute community-acquired pneumonia (< 48 hours after admission),
Who may be able to join
- Adult subject (≥ 18 years old),
- acute community-acquired pneumonia (< 48 hours after admission),
- admitted from the Emergency Department, consultation or home.
- Subject not objecting to the reuse of their data for scientific research purposes
Who cannot join
- Expressed refusal to reuse data for scientific research purposes.
- bronchitis, acute nosocomial pneumopathy, secondary infection due to bronchial dilation.
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Service de Pneumologie - CHU de Strasbourg - France
Strasbourg, 67091
Loïc KASSEGNE, MD, 33 3 69 55 01 88, loic.kassegne@chru-strasbourg.fr
Loïc KASSEGNE, MD
About this study
Official title: Inventory of the Management of Acute Community-acquired Pneumonia in the Pneumology Department of the Strasbourg University Hospitals
Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact. Viruses (rhinovirus, respiratory syncitial virus, influenza virus for the most common) and Streptococcus pneumoniae are the most frequently encountered pathogens. However, more than half of the PACs have no microbiological documentation. The management of CAPs is based on national and international recommendations. Several studies have shown imperfect compliance by clinicians with recommendations with a prognostic impact.
The various published studies insist on the variability of the incidence, the type of pathogen, the severity and the economic impact, depending on the series. They also insist on the need to know the local epidemiology, in particular microbiological, in order to adapt the recommendations.
Read the detailed description
The objective of the study is to determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia.
- Conditions
- Infection, Lung Parenchyma
- Keywords
- Community-acquired Pneumonia, Infection, Lung parenchyma, Rhinovirus, Respiratory syncitial virus, Influenza virus, Streptococcus pneumoniae
- Medical subject headings
- Infections, Community-Acquired Pneumonia
What is being measured
The primary outcome is the main question the study is designed to answer.
Retrospectively determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia
Retrospective analysis of health data from patients' medical records
Measured: Files analysed retrospectively from January 01, 2015 to December 31, 2019 will be examined
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2022
- Study start9 Sep 2022
- Primary completionMar 2025 (estimated)
- Study completion9 Mar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infection, Lung ParenchymaStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05661513
- Sponsor's protocol ID
- 8718
- Acronym
- PPAC
- Status last verified
- Dec 2022
- First submitted
- 14 Dec 2022
- Last updated
- 19 Dec 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inventory of the Management of Acute Community-acquired Pneumonia in the Pneumology Department of the Strasbourg University Hospitals
- ClinicalTrials.gov ID
- NCT05661513
- Acronym / sponsor ID
- PPAC / 8718
- Conditions
- Infection, Lung Parenchyma
- Keywords
- Community-acquired Pneumonia, Infection, Lung parenchyma, Rhinovirus, Respiratory syncitial virus, Influenza virus, Streptococcus pneumoniae
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 9 Sep 2022 (actual)
- Primary completion
- Mar 2025 (estimated)
- Study completion
- 9 Mar 2025 (estimated)
- First posted
- 22 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact. Viruses (rhinovirus, respiratory syncitial virus, influenza virus for the most common) and Streptococcus pneumoniae are the most frequently encountered pathogens. However, more than half of the PACs have no microbiological documentation. The management of CAPs is based on national and international recommendations. Several studies have shown imperfect compliance by clinicians with recommendations with a prognostic impact.
The various published studies insist on the variability of the incidence, the type of pathogen, the severity and the economic impact, depending on the series. They also insist on the need to know the local epidemiology, in particular microbiological, in order to adapt the recommendations.
Detailed description
The objective of the study is to determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patients with acute community-acquired pneumonia (< 48 hours after admission),
Key inclusion criteria (4 listed)
- Adult subject (≥ 18 years old),
- acute community-acquired pneumonia (< 48 hours after admission),
- admitted from the Emergency Department, consultation or home.
- Subject not objecting to the reuse of their data for scientific research purposes
Key exclusion criteria (2 listed)
- Expressed refusal to reuse data for scientific research purposes.
- bronchitis, acute nosocomial pneumopathy, secondary infection due to bronchial dilation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Retrospectively determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia
Time frame: Files analysed retrospectively from January 01, 2015 to December 31, 2019 will be examined
Retrospective analysis of health data from patients' medical records
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2023.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infection, Lung Parenchyma, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Loïc KASSEGNE, MD (33 3 69 55 01 88, loic.kassegne@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retrospectively determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia (time frame: Files analysed retrospectively from January 01, 2015 to December 31, 2019 will be examined). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2023.